Target Name: GRM7
NCBI ID: G2917
Other Name(s): GRM7 variant 1 | GLUR7 | GPRC1G | MGLUR7 | GRM7 variant 2 | hmGluR7a | mglu7 receptor | GRM7_HUMAN | protein phosphatase 1, regulatory subunit 87 | Glutamate metabotropic receptor 7, transcript variant 2 | NEDSHBA | mGluR7 | Metabotropic glutamate receptor 7 | MGLU7 | Glutamate metabotropic receptor 7, transcript variant 1 | Metabotropic glutamate receptor 7 (isoform b) | hmGluR7b | glutamate receptor, metabotropic 7 | PPP1R87 | Metabotropic glutamate receptor 7 (isoform a) | glutamate metabotropic receptor 7

Study on GATA-7: Structure, Function and Potential as A Drug Target

Growth arrest and DNA damage-inducible gene 7 (GATA-7) is a non-coding RNA molecule that plays a crucial role in regulating cellular growth and development. Mutations in GATA-7 have been linked to a variety of diseases, including obesity, cancer, and neurodevelopmental disorders. Despite its importance, little is known about GATA-7 itself, making it an attractive target for researchers to study. In this article, we will explore GATA-7, its function, and potential as a drug target.

GATA-7: Structure and Function

GATA-7 is a non-coding RNA molecule that contains 214 amino acid residues. It is expressed in a variety of tissues, including fetal brain, heart, and muscle. GATA-7 is primarily localized to the nucleus and has been shown to interact with the transcription factor, p53.

GATA-7 has been shown to play a role in regulating cellular processes such as cell growth, apoptosis, and DNA replication. It has also been linked to a variety of diseases, including obesity, cancer, and neurodevelopmental disorders.

Mutations in GATA-7 have been linked to a variety of diseases, including obesity, cancer, and neurodevelopmental disorders. For example, a study by Li et al. found that individuals with the obese-associated genomic region (OAR) had reduced levels of GATA-7 and were more likely to develop obesity. Similarly, a study by Zhang et al. found that individuals with the neurodevelopmental disorder, Fragile X syndrome, had decreased levels of GATA-7 and were more likely to have cognitive impairments.

GATA-7 as a Drug Target

GATA-7 has the potential to be a drug target due to its involvement in a variety of diseases. One potential mechanism by which GATA-7 could be targeted is through its role in regulating cellular processes that are associated with disease.

For example, GATA-7 has been shown to play a role in the regulation of cell death. In a study by Wang et al. (8), GATA-7 was shown to be involved in the regulation of cell death, specifically apoptosis. The authors found that GATA-7 levels increased in response to an apoptosis-inducing agent and that inhibition of GATA-7 led to increased cell survival.

Another potential mechanism by which GATA-7 could be targeted is through its role in the regulation of cellular processes that are associated with cancer. In a study by Liu et al. (9), GATA-7 was shown to be involved in the regulation of cell proliferation and the transition to a state of quiescence in cancer cells. The authors found that GATA-7 levels increased in response to an indicator of cell proliferation and that inhibition of GATA-7 led to a decrease in cell proliferation.

GATA-7 has also been shown to be involved in the regulation of neurodevelopmental development. In a study by James et al. (10), GATA-7 was shown to play a role in the regulation of neuron survival and differentiation in the developing brain. The authors found that GATA-7 levels were decreased in the brains of individuals with neurodevelopmental disorders and that inhibition of GATA-7 led to a decrease in neuron survival.

Conclusion

GATA-7 is a non-coding RNA molecule that plays a crucial role in regulating cellular growth and development. Mutations in GATA-7 have been linked to a variety of diseases, including obesity, cancer, and neurodevelopmental disorders. As a result, GATA-7 is an attractive target for researchers to study and potential drug targets. Further research is needed to fully understand the role of GATA-7 in

Protein Name: Glutamate Metabotropic Receptor 7

Functions: G-protein coupled receptor activated by glutamate that regulates axon outgrowth through the MAPK-cAMP-PKA signaling pathway during neuronal development (PubMed:33500274). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase that it inhibits (PubMed:9473604)

More Common Targets

GRM7-AS3 | GRM8 | GRM8-AS1 | GRN | Growth Factor Receptor-Bound Protein | GRP | GRPEL1 | GRPEL2 | GRPEL2-AS1 | GRPR | GRSF1 | GRTP1 | GRTP1-AS1 | GRWD1 | GRXCR1 | GRXCR2 | GS1-24F4.2 | GS1-600G8.3 | GSAP | GSC | GSC2 | GSDMA | GSDMB | GSDMC | GSDMD | GSDME | GSE1 | GSEC | GSG1 | GSG1L | GSG1L2 | GSK3A | GSK3B | GSKIP | GSN | GSPT1 | GSPT2 | GSR | GSS | GSTA1 | GSTA12P | GSTA2 | GSTA3 | GSTA4 | GSTA5 | GSTA7P | GSTCD | GSTK1 | GSTM1 | GSTM2 | GSTM2P1 | GSTM3 | GSTM4 | GSTM5 | GSTM5P1 | GSTO1 | GSTO2 | GSTP1 | GSTT1 | GSTT2 | GSTT2B | GSTT4 | GSTTP2 | GSTZ1 | GSX1 | GSX2 | GTDC1 | GTF2A1 | GTF2A1L | GTF2A2 | GTF2B | GTF2E1 | GTF2E2 | GTF2F1 | GTF2F2 | GTF2H1 | GTF2H2 | GTF2H2B | GTF2H2C | GTF2H2C_2 | GTF2H3 | GTF2H4 | GTF2H5 | GTF2I | GTF2I-AS1 | GTF2IP1 | GTF2IP12 | GTF2IP20 | GTF2IP4 | GTF2IP7 | GTF2IRD1 | GTF2IRD1P1 | GTF2IRD2 | GTF2IRD2B | GTF2IRD2P1 | GTF3A | GTF3AP5 | GTF3C1 | GTF3C2 | GTF3C2-AS1